ArriVent Biopharma price target lowered to $18 from $45 at Truist
PT cut; bearish.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
PT cut; bearish.
What happened, with direct paths to the underlying reporting
Truist reduces AVBP's price target to $18 from $45.
Target: $18
Posted price: $15.09
Analyst firm: Truist Financial
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.